Benjamin Hilton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benjamin Hilton has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Barbara R. DuPont
Diagnostic Laboratories, Greenwood Genetic Center, Greenwood, USA
3 shared publications- Barbara R. DuPont
Greenwood Genetic Center, Greenwood, SC 29646, USA
3 shared publications - Alex Hastie
Arima Genomics, Carlsbad, California, United States
2 shared publications - Alka Chaubey
BioNano Genomics, San Diego, CA 92121, USA
2 shared publications Angie Lichty
Greenwood Genetic Center, Greenwood Diagnostic Labs, Greenwood, USA
2 shared publications- Ashis Kumar Mondal
Department of Pathology, Augusta University, Augusta, GA 30912, USA
2 shared publications
Latest Publications
- 20 March 2024
- Published by Springer Nature
- p. 17-30
Diagnostic Methods for Ring Chromosomes
- Open Access
Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation
Homologous recombination deficiency (HRD) is characterized by the inability of a cell to repair the double-stranded breaks using the homologous recombination repair (HRR) pathway. The deficiency of the HRR pathway results in defective DNA repair, leading to genomic instability and tumorigenesis. The presence of HRD has been found to make tumors sensitive to ICL-inducing platinum-based therapies and poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors (PARPi). However, there are no standardized methods to measure and report HRD phenotypes. Herein, we compare optical genome mapping (OGM), chromosomal microarray (CMA), and a 523-gene NGS panel for HRD score calculations. This retrospective study included the analysis of 196 samples, of which 10 were gliomas, 176 were hematological malignancy samples, and 10 were controls. The 10 gliomas were evaluated with both CMA and OGM, and 30 hematological malignancy samples were evaluated with both the NGS panel and OGM. To verify the scores in a larger cohort, 135 cases were evaluated with the NGS panel and 71 cases with OGM. The HRD scores were calculated using a combination of three HRD signatures that included loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale transitions (LST). In the ten glioma cases analyzed with OGM and CMA using the same DNA (to remove any tumor percentage bias), the HRD scores (mean ± SEM) were 13.2 (±4.2) with OGM compared to 3.7 (±1.4) with CMA. In the 30 hematological malignancy cases analyzed with OGM and the 523-gene NGS panel, the HRD scores were 7.6 (±2.2) with OGM compared to 2.6 (±0.8) with the 523-gene NGS panel. OGM detected 70.8% and 66.8% of additional variants that are considered HRD signatures in gliomas and hematological malignancies, respectively. The higher sensitivity of OGM to capture HRD signature variants might enable a more accurate and precise correlation with response to PARPi and platinum-based drugs. This study reveals HRD signatures that are cryptic to current standard of care (SOC) methods used for assessing the HRD phenotype and presents OGM as an attractive alternative with higher resolution and sensitivity to accurately assess the HRD phenotype.
Open AccessOptical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation
Homologous recombination deficiency (HRD) is characterized by the inability of a cell to repair the double-stranded breaks using the homologous recombination repair (HRR) pathway. The deficiency of the HRR pathway results in defective DNA repair, leading to genomic instability and tumorigenesis. The presence of HRD has been found to make tumors sensitive to ICL-inducing platinum-based therapies and poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors (PARPi). However, there are no standardized methods to measure and report HRD phenotypes. Herein, we compare optical genome mapping (OGM), chromosomal microarray (CMA), and a 523-gene NGS panel for HRD score calculations. This retrospective study included the analysis of 196 samples, of which 10 were gliomas, 176 were hematological malignancy samples, and 10 were controls. The 10 gliomas were evaluated with both CMA and OGM, and 30 hematological malignancy samples were evaluated with both the NGS panel and OGM. To verify the scores in a larger cohort, 135 cases were evaluated with the NGS panel and 71 cases with OGM. The HRD scores were calculated using a combination of three HRD signatures that included loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale transitions (LST). In the ten glioma cases analyzed with OGM and CMA using the same DNA (to remove any tumor percentage bias), the HRD scores (mean ± SEM) were 13.2 (±4.2) with OGM compared to 3.7 (±1.4) with CMA. In the 30 hematological malignancy cases analyzed with OGM and the 523-gene NGS panel, the HRD scores were 7.6 (±2.2) with OGM compared to 2.6 (±0.8) with the 523-gene NGS panel. OGM detected 70.8% and 66.8% of additional variants that are considered HRD signatures in gliomas and hematological malignancies, respectively. The higher sensitivity of OGM to capture HRD signature variants might enable a more accurate and precise correlation with response to PARPi and platinum-based drugs. This study reveals HRD signatures that are cryptic to current standard of care (SOC) methods used for assessing the HRD phenotype and presents OGM as an attractive alternative with higher resolution and sensitivity to accurately assess the HRD phenotype.
- 29 July 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (8) , 536-539
Bench to Bedside
- 29 July 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (8) , 536-539
Bench to Bedside
- Open Access
- 10 July 2023
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 16 (1) , 1-11
17q25.3 copy number changes: association with neurodevelopmental disorders and cardiac malformation
Copy number variants (CNVs) have been identified as common genomic variants that play a significant role in inter-individual variability. Conversely, rare recurrent CNVs have been found to be causal for many disorders with well-established genotype–phenotype relationships. However, the phenotypic implications of rare non-recurrent CNVs remain poorly understood. Herein, we re-investigated 18,542 cases reported from chromosomal microarray at Greenwood Genetic Center from 2010 to 2022 and identified 15 cases with CNVs involving the 17q25.3 region. We report the detailed clinical features of these subjects, and compare with the cases reported in the literature to determine genotype–phenotype correlations for a subset of genes in this region. The CNVs in the 17q25.3 region were found to be rare events, with a prevalence of 0.08% (15/18542) observed in our cohort. The CNVs were dispersed across the entire 17q25.3 region with variable breakpoints and no smallest region of overlap. The subjects presented with a wide range of clinical features, with neurodevelopmental disorders (autism spectrum disorder, intellectual disability, developmental delay) being the most common features (80%), then expressive language disorder (33%), and finally cardiovascular malformations (26%). The association of CNVs involving the critical gene-rich region of 17q25.3 with neurodevelopmental disorders and cardiac malformation, implicates several genes as plausible drivers for these events.
- 10 July 2023
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 16 (1) , 1-11
Open Access17q25.3 copy number changes: association with neurodevelopmental disorders and cardiac malformation
Copy number variants (CNVs) have been identified as common genomic variants that play a significant role in inter-individual variability. Conversely, rare recurrent CNVs have been found to be causal for many disorders with well-established genotype–phenotype relationships. However, the phenotypic implications of rare non-recurrent CNVs remain poorly understood. Herein, we re-investigated 18,542 cases reported from chromosomal microarray at Greenwood Genetic Center from 2010 to 2022 and identified 15 cases with CNVs involving the 17q25.3 region. We report the detailed clinical features of these subjects, and compare with the cases reported in the literature to determine genotype–phenotype correlations for a subset of genes in this region. The CNVs in the 17q25.3 region were found to be rare events, with a prevalence of 0.08% (15/18542) observed in our cohort. The CNVs were dispersed across the entire 17q25.3 region with variable breakpoints and no smallest region of overlap. The subjects presented with a wide range of clinical features, with neurodevelopmental disorders (autism spectrum disorder, intellectual disability, developmental delay) being the most common features (80%), then expressive language disorder (33%), and finally cardiovascular malformations (26%). The association of CNVs involving the critical gene-rich region of 17q25.3 with neurodevelopmental disorders and cardiac malformation, implicates several genes as plausible drivers for these events.
- Open Access
Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers
The standard-of-care (SOC) for genomic testing of myeloid cancers primarily relies on karyotyping/fluorescent in situ hybridization (FISH) (cytogenetic analysis) and targeted gene panels (usually ≤54 genes) that harbor hotspot pathogenic variants (molecular genetic analysis). Despite this combinatorial approach, ~50% of myeloid cancer genomes remain cytogenetically normal, and the limited sequencing variant profiles obtained from targeted panels are unable to resolve the molecular etiology of many myeloid tumors. In this study, we evaluated the performance and clinical utility of combinatorial use of optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for comprehensive genomic profiling of 30 myeloid tumors and compared it to SOC cytogenetic methods (karyotyping and FISH) and a 54-gene NGS panel. OGM and the 523-gene NGS panel had an analytical concordance of 100% with karyotyping, FISH, and the 54-gene panel, respectively. Importantly, the IPSS-R cytogenetic risk group changed from very good/good to very poor in 22% of MDS (2/9) cases based on comprehensive profiling (karyotyping, FISH, and 54-gene panel vs. OGM and 523-gene panel), while additionally identifying six compound heterozygous events of potential clinical relevance in six cases (6/30, 20%). This cost-effective approach of using OGM and a 523-gene NGS panel for comprehensive genomic profiling of myeloid cancers demonstrated increased yield of actionable targets that can potentially result in improved clinical outcomes.
Open AccessClinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers
The standard-of-care (SOC) for genomic testing of myeloid cancers primarily relies on karyotyping/fluorescent in situ hybridization (FISH) (cytogenetic analysis) and targeted gene panels (usually ≤54 genes) that harbor hotspot pathogenic variants (molecular genetic analysis). Despite this combinatorial approach, ~50% of myeloid cancer genomes remain cytogenetically normal, and the limited sequencing variant profiles obtained from targeted panels are unable to resolve the molecular etiology of many myeloid tumors. In this study, we evaluated the performance and clinical utility of combinatorial use of optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for comprehensive genomic profiling of 30 myeloid tumors and compared it to SOC cytogenetic methods (karyotyping and FISH) and a 54-gene NGS panel. OGM and the 523-gene NGS panel had an analytical concordance of 100% with karyotyping, FISH, and the 54-gene panel, respectively. Importantly, the IPSS-R cytogenetic risk group changed from very good/good to very poor in 22% of MDS (2/9) cases based on comprehensive profiling (karyotyping, FISH, and 54-gene panel vs. OGM and 523-gene panel), while additionally identifying six compound heterozygous events of potential clinical relevance in six cases (6/30, 20%). This cost-effective approach of using OGM and a 523-gene NGS panel for comprehensive genomic profiling of myeloid cancers demonstrated increased yield of actionable targets that can potentially result in improved clinical outcomes.
- Open Access
- 1 February 2023
- Published by Springer Nature in Research Square
17q25.3 copy number changes: association with neurodevelopmental disorders and cardiac malformation
Copy number variants (CNVs) have been identified as common genomic variants that play a significant role in inter-individual variability. The rare recurrent CNVs have been found to be causal for many disorders with well-established genotype-phenotype relationships. However, the phenotypic implications of rare non-recurrent CNVs remain poorly understood. Herein, we re-investigated 18,664 cases reported from chromosomal microarray (CMA) at Greenwood Genetic Center from 2010 to 2022 and identified 15 cases with CNVs involving the 17q25.3 region. We report the detailed clinical features of these subjects, and compare with the cases reported in the literature to determine genotype-phenotype correlation for a subset of genes in this region.The CNVs in the 17q25.3 region were found to be rare events, with a prevalence of 0.0008% (15/18664) observed in our cohort. The CNVs spanned the entire 17q25.3 region with variable breakpoints and no smallest region of overlap. The subjects demonstrated a wide range of clinical features, with neurodevelopmental disorders (ASD, ID, DD) being the most common feature in 80% of cases, expressive language disorder in 33% of cases, followed by cardiovascular malformations in 26% of cases. The association of the critical gene-rich region of 17q25.3 with neurodevelopmental disorders and cardiac malformation, implicates several genes as plausible drivers for these events.
- 1 February 2023
- Published by Springer Nature in Research Square
Open Access17q25.3 copy number changes: association with neurodevelopmental disorders and cardiac malformation
Copy number variants (CNVs) have been identified as common genomic variants that play a significant role in inter-individual variability. The rare recurrent CNVs have been found to be causal for many disorders with well-established genotype-phenotype relationships. However, the phenotypic implications of rare non-recurrent CNVs remain poorly understood. Herein, we re-investigated 18,664 cases reported from chromosomal microarray (CMA) at Greenwood Genetic Center from 2010 to 2022 and identified 15 cases with CNVs involving the 17q25.3 region. We report the detailed clinical features of these subjects, and compare with the cases reported in the literature to determine genotype-phenotype correlation for a subset of genes in this region.The CNVs in the 17q25.3 region were found to be rare events, with a prevalence of 0.0008% (15/18664) observed in our cohort. The CNVs spanned the entire 17q25.3 region with variable breakpoints and no smallest region of overlap. The subjects demonstrated a wide range of clinical features, with neurodevelopmental disorders (ASD, ID, DD) being the most common feature in 80% of cases, expressive language disorder in 33% of cases, followed by cardiovascular malformations in 26% of cases. The association of the critical gene-rich region of 17q25.3 with neurodevelopmental disorders and cardiac malformation, implicates several genes as plausible drivers for these events.
- 19 January 2023
- Published by Springer Nature in Chromosome Research
- Vol. 31 (1) , 1-10
Paternal UPD14 with sSMC derived from chromosome 14 in Kagami–Ogata syndrome
- 19 January 2023
- Published by Springer Nature in Chromosome Research
- Vol. 31 (1) , 1-10
Paternal UPD14 with sSMC derived from chromosome 14 in Kagami–Ogata syndrome
- Open Access
- 18 November 2022
- Published by Springer Nature in Research Square
Paternal UPD14 with sSMC derived from chromosome 14 in Kagami-Ogata syndrome
Uniparental disomy (UPD) has been associated with several well-characterized disorders due to abnormal imprinting of the underlying genes. Depending on the parent-of-origin, paternal and maternal UPD are frequently associated with clinically distinct imprinting disorders. Here we report a neonatal case that was referred to Greenwood Genetic Center for clinical genetic testing. Prenatal ultrasound identified polyhydramnios and congenital cardiac anomalies and neonatal examination revealed a prune-like belly and bowel obstruction. Taking advantage of a variety of cytogenetic and molecular genetic approaches, we identified the presence of a small supernumerary marker chromosome (sSMC) associated with a complex chromosomal rearrangement derived from 14q11.2 and absence of heterozygosity on the chromosome 14q, indicative of uniparental isodisomy for chromosome 14. In addition, microsatellite DNA analysis of chromosome 14 showed UPD14 in this patient is paternal in origin, which is consistent with a clinical diagnosis of Kagami-Ogata syndrome (KOS). To our knowledge, this is the first case report of KOS resulting from paternal UPD14 and presence of sSMC with complex chromosomal rearrangement involving 14q11.2 without evidence of mosaicism.
- 18 November 2022
- Published by Springer Nature in Research Square
Open AccessPaternal UPD14 with sSMC derived from chromosome 14 in Kagami-Ogata syndrome
Uniparental disomy (UPD) has been associated with several well-characterized disorders due to abnormal imprinting of the underlying genes. Depending on the parent-of-origin, paternal and maternal UPD are frequently associated with clinically distinct imprinting disorders. Here we report a neonatal case that was referred to Greenwood Genetic Center for clinical genetic testing. Prenatal ultrasound identified polyhydramnios and congenital cardiac anomalies and neonatal examination revealed a prune-like belly and bowel obstruction. Taking advantage of a variety of cytogenetic and molecular genetic approaches, we identified the presence of a small supernumerary marker chromosome (sSMC) associated with a complex chromosomal rearrangement derived from 14q11.2 and absence of heterozygosity on the chromosome 14q, indicative of uniparental isodisomy for chromosome 14. In addition, microsatellite DNA analysis of chromosome 14 showed UPD14 in this patient is paternal in origin, which is consistent with a clinical diagnosis of Kagami-Ogata syndrome (KOS). To our knowledge, this is the first case report of KOS resulting from paternal UPD14 and presence of sSMC with complex chromosomal rearrangement involving 14q11.2 without evidence of mosaicism.